Bellissimo Teresa, Ganci Federica, Gallo Enzo, Sacconi Andrea, Tito Claudia, De Angelis Luciana, Pulito Claudio, Masciarelli Silvia, Diso Daniele, Anile Marco, Petrozza Vincenzo, Giangaspero Felice, Pescarmona Edoardo, Facciolo Francesco, Venuta Federico, Marino Mirella, Blandino Giovanni, Fazi Francesco
Deptartment of Anatomical, Histological, Forensic & Orthopaedic Sciences, Section of Histology & Medical Embryology, Sapienza University of Rome, Rome, Italy.
Oncogenomic and Epigenetic Unit, "Regina Elena" National Cancer Institute, Rome, Italy.
Mol Cancer. 2017 May 10;16(1):88. doi: 10.1186/s12943-017-0655-2.
Thymoma and thymic carcinoma are the most frequent subtypes of thymic epithelial tumors (TETs). A relevant advance in TET management could derive from a deeper molecular characterization of these neoplasms. We previously identified a set of microRNA (miRNAs) differentially expressed in TETs and normal thymic tissues and among the most significantly deregulated we described the down-regulation of miR-145-5p in TET. Here we describe the mRNAs diversely regulated in TETs and analyze the correlation between these and the miRNAs previously identified, focusing in particular on miR-145-5p. Then, we examine the functional role of miR-145-5p in TETs and its epigenetic transcriptional regulation.
mRNAs expression profiling of a cohort of fresh frozen TETs and normal tissues was performed by microarray analysis. MiR-145-5p role in TETs was evaluated in vitro, modulating its expression in a Thymic Carcinoma (TC1889) cell line. Epigenetic transcriptional regulation of miR-145-5p was examined by treating the TC1889 cell line with the HDAC inhibitor Valproic Acid (VPA).
Starting from the identification of a 69-gene signature of miR-145-5p putative target mRNAs, whose expression was inversely correlated to that of miR-145-5p, we followed the expression of some of them in vitro upon overexpression of miR-145-5p; we observed that this resulted in the down-regulation of the target genes, impacting on TETs cancerous phenotype. We also found that VPA treatment of TC1889 cells led to miR-145-5p up-regulation and concomitant down-regulation of miR-145-5p target genes and exhibited antitumor effects, as indicated by the induction of cell cycle arrest and by the reduction of cell viability, colony forming ability and migration capability. The importance of miR-145-5p up-regulation mediated by VPA is evidenced by the fact that hampering miR-145-5p activity by a LNA inhibitor reduced the impact of VPA treatment on cell viability and colony forming ability of TET cells. Finally, we observed that VPA was also able to enhance the response of TET cells to cisplatin and erlotinib.
Altogether our results suggest that the epigenetic regulation of miR-145-5p expression, as well as the modulation of its functional targets, could be relevant players in tumor progression and treatment response in TETs.
胸腺瘤和胸腺癌是胸腺上皮肿瘤(TETs)最常见的亚型。TET管理方面的一项相关进展可能源于对这些肿瘤更深入的分子特征分析。我们之前鉴定出一组在TET和正常胸腺组织中差异表达的微小RNA(miRNA),在最显著失调的miRNA中,我们描述了TET中miR-145-5p的下调。在此,我们描述在TET中受到不同调控的mRNA,并分析这些mRNA与之前鉴定的miRNA之间的相关性,尤其聚焦于miR-145-5p。然后,我们研究miR-145-5p在TET中的功能作用及其表观遗传转录调控。
通过微阵列分析对一组新鲜冷冻的TET和正常组织进行mRNA表达谱分析。在体外评估miR-145-5p在TET中的作用,在胸腺癌(TC1889)细胞系中调节其表达。通过用组蛋白去乙酰化酶抑制剂丙戊酸(VPA)处理TC1889细胞系来研究miR-145-5p的表观遗传转录调控。
从鉴定出69个基因的miR-145-5p假定靶mRNA特征开始,其表达与miR-145-5p的表达呈负相关,我们在体外过表达miR-145-5p后追踪其中一些基因的表达;我们观察到这导致靶基因下调,影响TET的癌性表型。我们还发现用VPA处理TC1889细胞导致miR-145-5p上调以及miR-145-5p靶基因的伴随下调,并表现出抗肿瘤作用,如诱导细胞周期停滞以及降低细胞活力、集落形成能力和迁移能力所示。LNA抑制剂阻碍miR-145-5p活性会降低VPA处理对TET细胞活力和集落形成能力的影响,这一事实证明了VPA介导的miR-145-5p上调的重要性。最后,我们观察到VPA还能够增强TET细胞对顺铂和厄洛替尼的反应。
总之,我们的结果表明miR-145-5p表达的表观遗传调控及其功能靶标的调节可能是TET肿瘤进展和治疗反应中的重要因素。